CA2310926A1 - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents

A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Download PDF

Info

Publication number
CA2310926A1
CA2310926A1 CA002310926A CA2310926A CA2310926A1 CA 2310926 A1 CA2310926 A1 CA 2310926A1 CA 002310926 A CA002310926 A CA 002310926A CA 2310926 A CA2310926 A CA 2310926A CA 2310926 A1 CA2310926 A1 CA 2310926A1
Authority
CA
Canada
Prior art keywords
galantamine
alzheimer
disease
treatment
neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002310926A
Other languages
French (fr)
Other versions
CA2310926C (en
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica N.V.
Wim Louis Julien Parys
Michael Pontecorvo
Janssen Pharmaceutica Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V., Wim Louis Julien Parys, Michael Pontecorvo, Janssen Pharmaceutica Inc. filed Critical Janssen Pharmaceutica N.V.
Publication of CA2310926A1 publication Critical patent/CA2310926A1/en
Application granted granted Critical
Publication of CA2310926C publication Critical patent/CA2310926C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Galantamine has be used in the treatment of a number of chronic diseases.
Galantamine has been found to be safe and effective in the treatment of Alzheimer's disease.
Neuropsychiatric disorders are often associated with Alzheimer's disease. It is demonstrated that galantamine is also effective in reducing or stabilizing the incidence of neuropsychiatric behaviour seen in Alzheimer's patients.
CA002310926A 2000-04-03 2000-06-27 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Expired - Lifetime CA2310926C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03

Publications (2)

Publication Number Publication Date
CA2310926A1 true CA2310926A1 (en) 2000-10-04
CA2310926C CA2310926C (en) 2002-10-15

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002310926A Expired - Lifetime CA2310926C (en) 2000-04-03 2000-06-27 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Country Status (20)

Country Link
EP (1) EP1272192A2 (en)
JP (1) JP2003528913A (en)
KR (1) KR20020086911A (en)
CN (1) CN1430514A (en)
AU (2) AU6584401A (en)
BG (1) BG107093A (en)
BR (1) BR0109770A (en)
CA (1) CA2310926C (en)
CZ (1) CZ20023543A3 (en)
EE (1) EE200200554A (en)
HR (1) HRP20020778A2 (en)
HU (1) HUP0300566A3 (en)
IL (1) IL152061A0 (en)
MX (1) MXPA02009777A (en)
NO (1) NO20024746L (en)
PL (1) PL361272A1 (en)
RU (1) RU2002129298A (en)
SK (1) SK15422002A3 (en)
WO (1) WO2001074339A2 (en)
ZA (1) ZA200207935B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
RU2357734C2 (en) * 2003-07-25 2009-06-10 Ф.Хоффманн-Ля Рош Аг COMBINATION OF mGluR2 RECEPTOR ANTAGONIST AND AChE ENZYME INHIBITOR FOR ACUTE ANDN/OR CHRONIC NEURALGIC DISEASES
DE10338544B4 (en) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccal formulations of galanthamine and their applications
MX2010010460A (en) 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Use and composition for treating dementia.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (en) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements
CN107847504A (en) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 The galanthamine of amyloid-beta is removed
WO2023036105A1 (en) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Method for treating neurodegenerative disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
JP5558648B2 (en) 1998-11-23 2014-07-23 デイビス、ボニー Administration formulation for acetylcholinesterase inhibitors
EP1140105B1 (en) * 1998-12-24 2003-10-22 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Also Published As

Publication number Publication date
HRP20020778A2 (en) 2004-04-30
HUP0300566A2 (en) 2003-06-28
CA2310926C (en) 2002-10-15
WO2001074339A2 (en) 2001-10-11
SK15422002A3 (en) 2003-04-01
IL152061A0 (en) 2003-05-29
AU2001265844B2 (en) 2005-04-14
WO2001074339A3 (en) 2002-09-12
MXPA02009777A (en) 2003-03-27
BG107093A (en) 2003-06-30
KR20020086911A (en) 2002-11-20
RU2002129298A (en) 2004-03-27
HUP0300566A3 (en) 2004-10-28
PL361272A1 (en) 2004-10-04
NO20024746D0 (en) 2002-10-02
AU6584401A (en) 2001-10-15
EP1272192A2 (en) 2003-01-08
CN1430514A (en) 2003-07-16
CZ20023543A3 (en) 2003-03-12
EE200200554A (en) 2004-04-15
NO20024746L (en) 2002-11-28
JP2003528913A (en) 2003-09-30
BR0109770A (en) 2003-02-04
ZA200207935B (en) 2004-01-30

Similar Documents

Publication Publication Date Title
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
EP1426375A3 (en) Analgesic spiroindole derivatives
AU2002359161A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
EP1596877A4 (en) Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions
ID27414A (en) NON-PEPTIDIL OBSTACLES FROM VLA-4 RELIEF BINDERS USING THE BENEFITS IN TREATMENT OF INFLAMATION, AUTOIMUN AND BREATHING DISEASES
USD483491S1 (en) Post treatment protector device
DK0668763T3 (en) Use of Phenserin in the manufacture of drugs for the treatment of cognitive disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU3247593A (en) Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
CA2310926A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
CA2310950A1 (en) An efficacious dosage regiment of galantamine that reduces side effects
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP0676200A3 (en) Use of eliprodil and of its enantiomers in the preparation of medicaments for the treatment of peripheral neuropathies and or central neurodegenerative diseases.
NL1010351A1 (en) Esters of carotenoids for use in the prevention and treatment of eye diseases.
NO990450L (en) Treatment of mental disorders
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
WO2001074364A3 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
EP1161948A3 (en) Pharmaceutical or food composition for treatment of brain edema
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity
USD365314S (en) Device to assist disabled persons
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2353808A1 (en) Agent for lowering endothelin levels

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200629